Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

New England Journal of Medicine

Volumn 351, Issue 3, 2004, Pages 229-240

  Jourdain, Gonzague ^a,b,c   Ngo Giang Huong, Nicole ^a,b,c   Le Coeur, Sophie ^c,d   Bowonwatanuwong, Chureeratana ^d   Kantipong, Pacharee ^d   Leechanachai, Pranee ^e   Ariyadej, Surabhon ^d   Leenasirimakul, Prattana ^d   Hammer, Scott ^f   Lallemant, Marc ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Inst Natl d'Etudes Demographiques ^*  (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e CHIANG MAI UNIVERSITY   (Thailand)

^f Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PLACEBO; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THAILAND; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION; ANTIBIOTIC RESISTANCE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FOLLOW UP; GENETICS; GENOTYPE; LABOR; MULTICENTER STUDY; MUTATION; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LABOR, OBSTETRIC; LOGISTIC MODELS; MUTATION; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; RISK FACTORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 3142762317     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa041305     Document Type: Article

References (29)

1. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557-64.
2. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women: Swiss Collaborative 'HIV and Pregnancy' Study. J Infect Dis 1999;179:705-8.
3. Ekpini RA, Nkengasong JN, Sibailly T, et al. Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002;16: 625-30.
4. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14:F111-F115.
5. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7.
6. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002;186: 181-8.
7. Morris L, Pillay C, Chezzi C, et al. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS 2003;17:1698-700.
8. Kantor R, Lee E, Johnston E, et al. Rapid flux in non-nucleoside reverse transcriptase inhibitor resistance mutations among subtype C HIV-1-infected women after single dose nevirapine. Antiviral Ther 2003;8:S85. abstract.
9. Chaix ML, Montcho C, Ekouevi DK, et al. Genotypic resistance analysis in women who received intrapartum nevirapine associated to a short course of zidovudine to prevent perinatal HIV-1 transmission: the Ditrame Plus ANRS 1201/02 Study, Abidjan, Côte d'Ivoire. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:657. abstract.
10. Chalermchokcharoenkit A, Asavapiriyanont S, Teeraratkul A, et al. Combination short-course zidovudine plus 2-dose nevirapine for prevention of mother-to-child transmission: safety, tolerance, transmission, and resistance results. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:96. abstract.
11. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:38. abstract.
12. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization, April 2002.
13. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351:217-28.
14. National Guidelines for the Clinical Management of HIV Infection in Children and Adults. Nonthaburi, Thailand: AIDS Division, Department of Communicable Disease Control, Ministry of Public Health, 2000:119-34.
15. Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003;11:215-21. (Also available at http://www.iasusa.org/ resistance_mutations.)
16. Higgins DG, Sharp PM. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 1988; 73:237-44.
17. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-82.
18. Perriere G, Gouy M. WWW-query: an on-line retrieval system for biological sequence banks. Biochimie 1996;78:364-9.
19. Lecossier D, Shulman N, Zolopa AR, Clavel F, Hance AJ. Resistance genotypes in patients failing nevirapine: co-existence of majority viral populations expressing Y181C and minority populations expressing K103N. Antiviral Ther 2003;8:S159. abstract.
20. Mellors J, Palmer S, Nissley D, et al. Low-frequency NNRTI-resistant variants contribute to failure of efavirenz-containing regimen, In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:39. abstract.
21. Eshleman SH, Jones D, Guay L, Musoke P, Mmiro F, Jackson JB. HIV-1 variants with diverse nevirapine resistance mutations emerge rapidly after single-dose nevirapine: HIVNET 012. Antiviral Ther 2003;8:S86. abstract.
22. Palmer S, Boltz V, Maldarelli F, et al. Emergence and long-term persistence of NNRTI-resistant variants in patients starting and stopping NNRTI-containing regimens. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:37. abstract.
23. Kearney M, Palmer S, Maldarelli F, et al. Single-genome sequencing is more sensitive than standard genotype analysis for detection of HIV-1 drug-resistance mutations. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:695. abstract.
24. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings: expert consultation, Geneva, 5-6 February 2004: a summary of main points from the meeting. (Accessed June 18, 2004, at http://www.who.int/3by5/arv_pmtct/en/.)
25. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, Md.: Department of Health and Human Services, March 23, 2004.
26. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003;17:1195-9.
27. Acosta EP, Bardeguez A, Zorrilla CD, e al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004;48:430-6.
28. Shepard KV. Important new safety information: re: clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with VIRAMUNE (nevirapine). Ridgefield, Conn.: Boehringer Ingelheim Pharmaceuticals, February 2004.
29. Jourdain G, Ngo-Giang-Huong N, Tungyai P, et al. Exposure to intrapartum single-dose nevirapine and subsequent maternal 6-month response to NNRTI-based regimens, In: Late breaker abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:41LB. abstract.